Mezalek Zoubida Tazi, Khibri Hajar, Ammouri Wafaa, Bouaouad Majdouline, Haidour Soukaina, Harmouche Hicham, Maamar Mouna, Adnaoui Mohamed
Internal Medicine Department, Ibn Sina University Hospital, Rabat, Morocco.
Clinical Hematology Department, Ibn Sina University Hospital, Rabat, Morocco.
Clin Appl Thromb Hemost. 2020 Jan-Dec;26:1076029620948137. doi: 10.1177/1076029620948137.
The SARS-CoV-2 virus caused a global pandemic within weeks, causing hundreds of thousands of people infected. Many patients with severe COVID-19 present with coagulation abnormalities, including increase D-dimers and fibrinogen. This coagulopathy is associated with an increased risk of death. Furthermore, a substantial proportion of patients with severe COVID-19 develop sometimes unrecognized, venous, and arterial thromboembolic complications. A better understanding of COVID-19 pathophysiology, in particular hemostatic disorders, will help to choose appropriate treatment strategies. A rigorous thrombotic risk assessment and the implementation of a suitable anticoagulation strategy are required. We review here the characteristics of COVID-19 coagulation laboratory findings in affected patients, the incidence of thromboembolic events and their specificities, and potential therapeutic interventions.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒在数周内引发了全球大流行，导致数十万人感染。许多重症冠状病毒病2019（COVID-19）患者存在凝血异常，包括D-二聚体和纤维蛋白原升高。这种凝血病与死亡风险增加相关。此外，相当一部分重症COVID-19患者会出现有时未被识别的静脉和动脉血栓栓塞并发症。更好地了解COVID-19的病理生理学，尤其是止血障碍，将有助于选择合适的治疗策略。需要进行严格的血栓形成风险评估并实施合适的抗凝策略。我们在此综述了受影响患者中COVID-19凝血实验室检查结果的特征、血栓栓塞事件的发生率及其特异性，以及潜在的治疗干预措施。
